Amol Akhade: It is time to take care of “missing third arm of the trial” syndrome
Amol Akhade shared his remarks on a study by Helen J Ross et al on X:
“Neoadjuvant Atezo before CTRT followed by Adjuvant Atezolizumab for one year. Small phase 2 study. 62 patients.
Authors feel that further studies to determine the role on neo adjuvant atezo before CTRT should be done I hope after the recent discussion for perioperative IO, FDA won’t approve any new trial design unless there is direct comparison between Adjuvant IO post CTRT vs neoadjuvant IO before CTRT.
It is time to take care of “missing third arm of the trial” syndrome.”
Source: Amol Akhade/X
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023